

# CONFERENCE SCHEDULE

THURSDAY, NOVEMBER 5, 2015

**3:00 p.m.-4:30 p.m.**

**Educational Session 1: Immunotherapy 101**

Veterans Memorial Auditorium

**Co-Chairpersons: Jolanda de Vries**, Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands, and **Mary L. (Nora) Disis**, University of Washington, Seattle, WA

**Immunity against cancer: How to be enhanced?\***

Jolanda de Vries

**Gene-modified T cells as biotherapeutics for cancer\***

Stephen Gottschalk, Baylor College of Medicine, Houston, TX

**Immune checkpoint inhibitors: Opportunities and challenges**

Mary L. (Nora) Disis

**4:45 p.m.-6:15 p.m.**

**Educational Session 2: Mutation Profiling/Return of Genetic Data**

Veterans Memorial Auditorium

**Co-Chairpersons: Lee J. Helman**, National Cancer Institute, Bethesda, MD, and **Sharon E. Plon**, Baylor College of Medicine, Houston, TX

**Introduction**

Lee J. Helman

**National-scale cancer sequencing and treatment response data integration in The Netherlands\***

Edwin Cuppen, University Medical Center Utrecht, Utrecht, The Netherlands

**Assigning clinical meaning to genomic data for cancer precision medicine**

Nikhil Wagle, Dana-Farber Cancer Institute, Boston, MA

**Delivering on the promise of personalized medicine**

Gordon B. Mills, The University of Texas MD Anderson Cancer Center, Houston, TX

**Returning germline results to cancer patients\***

Sharon E. Plon

\*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.

# CONFERENCE SCHEDULE

## **Closing remarks**

Sharon E. Plon

## **6:30 p.m.-8:00 p.m.**

### **Opening Networking Reception**

Grand/Liberty Ballroom, Sheraton Boston Hotel

## FRIDAY, NOVEMBER 6, 2015

## **7:00 a.m.-8:00 a.m.**

### **Continental Breakfast**

Boylston Street Hallway

## **8:00 a.m.-8:05 a.m.**

### **Welcome and Opening Remarks**

Veterans Memorial Auditorium

Levi A. Garraway, Dana-Farber Cancer Institute, Boston, MA

Lee J. Helman, National Cancer Institute, Bethesda, MD

Jean-Charles Soria, Institut Gustave-Roussy, Villejuif, France

## **8:05 a.m.-9:35 a.m.**

### **Keynote Lectures**

Veterans Memorial Auditorium

**Chairperson: Levi A. Garraway**, Dana-Farber Cancer Institute, Boston, MA

### **Updates on engineered T cells as cancer therapies\***

Carl H. June, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

### **Impact of gut microbiota in cancer development and therapeutics**

Laurence Zitvogel, Institut Gustave-Roussy, Villejuif, France

\*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.

**9:35 a.m.-10:00 a.m.**

**Break**

Boylston Street Hallway

**10:00 a.m.-12:00 p.m.**

**Plenary Session 1: Cellular Immunotherapy**

Veterans Memorial Auditorium

**Co-Chairpersons: Alexander M. M. Eggermont**, Institut Gustave-Roussy, Villejuif, France, and **Crystal L. Mackall**, National Cancer Institute, Bethesda, MD

**Mutation-driven drug development (targeted agents) vs. immunotherapeutics development**

Alexander M. M. Eggermont

**CAR therapy for cancer: Emerging insights**

Crystal L. Mackall

**TIL therapy in the era of immune checkpoint blockade\***

John B.A.G. Haanen, Netherlands Cancer Institute, Amsterdam, The Netherlands

**Engineering T cells with introduced TCRs to effectively target tumors**

Philip D. Greenberg, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA

**12:00 p.m.-4:00 p.m.**

**Exhibit Show**

Exhibit Hall C-D

**12:15 p.m.-3:15 p.m.**

**Poster Session A**

**(not eligible for CME credit)**

Exhibit Hall C-D

Angiogenesis and Antiangiogenesis Agents

Animal Models

Bioinformatics

Biomarkers

\*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.

# CONFERENCE SCHEDULE

Cell Cycle Regulators

Chemoprevention

Clinical Trials

EGFR/Her2

Epigenetic Regulation of Tumor Immunity

Genomics, Proteomics, and Target Discovery

Imaging

Immune Modulators

In Vitro and In Vivo Models for Targets

Metastasis and Invasion

mTOR/PI3-Kinase

New Molecular Targets

Pediatric-Early Drug Development

Signal Transduction Modulators

Therapeutic Agents: Biological

Therapeutic Agents: Other

Therapeutic Agents: Small Molecule Kinase Inhibitors

Topoisomerase Inhibitors

Tubulin-Interacting Agents

Tumor Immunology Targets

Tumor Microenvironment

Late-Breaking Posters

**12:15 p.m.-1:15 p.m.**

**AACR Chemistry in Cancer Research (CICR)**

**Working Group Town Hall Meeting**

**(not eligible for CME credit)**

Room 210

\*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.

**3:30 p.m.-4:10 p.m.**

**Spotlight on Proffered Papers 1**

**(not eligible for CME credit)**

Veterans Memorial Auditorium

**Chairperson: Levi A. Garraway**, Dana-Farber Cancer Institute, Boston, MA

**Acquisition of resistance to anti-EGFR therapy drives genomic heterogeneity and lesion-specific responses in colorectal cancer\*\***

Giulia Siravegna, University of Torino - IRCCS Candiolo, Candiolo, Italy

**Identification of a potent and selective chemical probe for exploring the role of CDK8/19 in cancer biology\*\*†**

Paul A. Clarke, Cancer Research UK Unit, The Institute of Cancer Research, London, United Kingdom

**Novel ceritinib resistance mechanisms: New resistant mutation, fibroblast growth factor receptor 3 overexpression and cMET amplification-mediated ceritinib resistance\*\*†**

Ryohei Katayama, Japanese Foundation for Cancer Research, Tokyo, Japan

**4:15 p.m.-6:15 p.m.**

**Concurrent Session 1: Radiomics: Imaging in the Context of Drug Development and Personalized Medicine**

Ballroom B

**Co-Chairpersons: Robert J. Gillies**, Moffitt Cancer Center and Research Institute, Tampa, FL, and **E. G. Elisabeth de Vries**, University Medical Center Groningen, Groningen, The Netherlands

**The radiology reading room of the future\***

Robert J. Gillies

**Incorporating molecular imaging methods in early drug development\***

E. G. Elisabeth de Vries

**Radiomics: The promise of imaging for personalized medicine**

Hugo Aerts, Brigham and Women's Hospital, Boston, MA

\*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.

†Short talk from proffered paper

# CONFERENCE SCHEDULE

## **Tumor growth rate (TGR) to identify pseudoprogression (PSPD) in cancer patients treated by anti-PD1 or anti-PD-L1**

Charles Ferté, Institut Gustave-Roussy, Villejuif, France

**4:15 p.m.-6:15 p.m.**

## **Concurrent Session 2: Liquid Biopsies to Monitor Clonal Evolution and Drug Resistance**

Veterans Memorial Auditorium

**Co-Chairpersons: Alberto Bardelli**, IRCC - University of Turin, Medical School, Candiolo, Italy, and **Luis A. Diaz**, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD

### **Analysis of circulating tumor DNA to monitor clonal evolution**

Muhammed Murtaza, Translational Genomics Research Institute, Phoenix, AZ

### **Comprehensive detection of structural alterations in the circulation of cancer patients\* (not eligible for CME credit)**

Mark Sausen, Personal Genome Diagnostics, Baltimore, MD

### **Heterogeneity, drug resistance, and clonal dynamics in colorectal cancers\***

Alberto Bardelli

Additional speaker to be announced

**4:15 p.m.-6:15 p.m.**

## **Concurrent Session 3: Handling Toxicities of Immune Checkpoints/Checkpoint Blockade**

Ballroom A

**Co-Chairpersons: Scott Gettinger**, Yale University, New Haven, CT, and **Antoine Italiano**, Institute Bergonié, Bordeaux, France

### **Toxicities from immunomodulatory antibodies: An overview\***

Antoine Italiano

### **Anti-PD-1/PD-L1 associated pneumonitis**

Scott Gettinger

\*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.

**Dermatological toxicities from CTLA-4 and PD-1 immune checkpoint inhibition**

Jennifer N. Choi, Yale University School of Medicine, New Haven, CT

**Autoimmune endocrine disease induced with checkpoint inhibitors**

Kevan Herold, Yale University School of Medicine, New Haven, CT

**4:15 p.m.-6:15 p.m.**

**Concurrent Session 4: Therapeutic Vaccines**

Ballroom C

**Co-Chairpersons:** **James L. Gulley**, National Cancer Institute, Bethesda, MD, and **Daniel E. Speiser**, Ludwig Cancer Research Center/University of Lausanne, Lausanne, Switzerland

**Introduction**

James L. Gulley

**Targeting the epithelial-mesenchymal transition via brachyury-based cancer vaccines\***

Claudia M. Palena, National Cancer Institute-CCR, Bethesda, MD

**Developing personalized neoantigen-based cancer vaccines**

Catherine J. Wu, Dana-Farber Cancer Institute, Boston, MA

**DNA vaccines as treatment for prostate cancer: Understanding mechanisms of resistance\***

Douglas G. McNeel, University of Wisconsin-Madison, Madison, WI

**Comprehensive analyses of tumor immunity with implications to cancer immunotherapies\*\*  
(not eligible for CME credit)**

Bo Li, Dana-Farber Cancer Institute, Brookline, MA

**Q&A/Discussion**

**Closing remarks**

Daniel E. Speiser

\*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.

†Short talk from proffered paper

# CONFERENCE SCHEDULE

SATURDAY, NOVEMBER 7, 2015

**7:00 a.m.-8:00 a.m.**

## **Continental Breakfast**

Boylston Street Hallway

**8:00 a.m.-10:00 a.m.**

## **Plenary Session 2: Immunotherapy Checkpoints**

Veterans Memorial Auditorium

**Co-Chairpersons: Paolo A. Ascierto**, Istituto Nazionale Tumori, Naples, Italy, and **Edward B. Garon**, University of California-Los Angeles, Santa Monica, CA

### **What we learned from immunotherapy in previous years\***

Paolo A. Ascierto

### **Progress in lung cancer treatment with immunotherapy\***

Edward B. Garon

### **Combination with/of immunotherapies\***

Christian Blank, Netherlands Cancer Institute, Amsterdam, The Netherlands

### **Biomarkers for response to PD-1/PD-L1 checkpoint blockade: PD-L1 and beyond**

Janis M. Taube, Johns Hopkins University, Baltimore, MD

**10:00 a.m.-10:20 a.m.**

## **Break**

Boylston Street Hallway

**10:20 a.m.-12:20 p.m.**

## **Plenary Session 3: Update on Targeting RAS and Cancer**

Veterans Memorial Auditorium

**Co-Chairpersons: Mariano Barbacid**, Spanish National Cancer Research Center (CNIO), Madrid, Spain, and **Frank McCormick**, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

\*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.



**Targeting K-RAS driven cancer\***

Mariano Barbacid

**Nontraditional chemical approaches to directly target K-RAS**

Kevan M. Shokat, University of California-San Francisco/  
Howard Hughes Medical Institute, San Francisco, CA

**K-RAS dependency in pancreatic cancer\***

David A. Tuveson, Cold Spring Harbor Laboratory,  
Cold Spring Harbor, NY

**Targeting K-RAS stemness**

Frank McCormick

**Drugging RAS into oblivion\***

Gregory L. Verdine, Harvard University and Warp Drive Bio,  
Cambridge, MA

**12:30 p.m.-4:00 p.m.**

**Exhibit Show**

Exhibit Hall C-D

**12:30 p.m.-3:30 p.m.**

**Poster Session B**

**(not eligible for CME credit)**

Exhibit Hall C-D

Biomarkers

Cellular Responses to Therapy

Clinical Trials

Drug Delivery

Drug Design

Drug Resistance and Modifiers

Drug Screening

Epigenetic Targets

Heat Shock Proteins

Immune Checkpoints

Immune Monitoring/Clinical Correlates

\*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.

# CONFERENCE SCHEDULE

MAPK pathways

Molecular Classification of Tumors

mTOR/PI3-Kinase

Natural Products

New Molecular Targets

Novel Assay Technology

Pharmacogenetics, Pharmacogenomics, and  
Therapeutic Response

Pharmacokinetics and Pharmacodynamics

Protein-Protein Interaction

Target Identification and Validation

Therapeutic Agents: Other

Therapeutic Agents: Small Molecule Kinase Inhibitors

Toxicology

Tumor Microenvironment

Other Topics

Late-Breaking Posters

**2:00 p.m.-3:15 p.m.**

**Regulatory Science and Policy Session:  
How to Achieve Breakthrough Therapy  
Designation in Oncology  
(not eligible for CME credit)**

**Speakers:**

George D. Demetri, Dana-Farber Cancer Institute,  
Boston, MA

Dickran Kazandjian, U.S. Food and Drug Administration,  
Silver Springs, MD

Eric H. Rubin, Merck Research Laboratories, North Wales, PA

David Kerstein, ARIAD Pharmaceuticals, Inc., Cambridge, MA

\*An extended abstract for this presentation is available in  
the online Proceedings or in the Program Guide app.

**3:45 p.m.-4:25 p.m.**

**Spotlight on Proffered Papers 2**

**(not eligible for CME credit)**

Veterans Memorial Auditorium

**Chairperson: Patricia M. LoRusso**, Yale Cancer Center, New Haven, CT

**Exceptional response to PD-1 antibody treatment in a POLE-mutant endometrial cancer\*\***

Janice M. Mehnert, Rutgers-The Cancer Institute of New Jersey, New Brunswick, NJ

**Phase 1b dose-escalation study of trametinib (MEKi) plus palbociclib (CDK4/6i) in patients with advanced solid tumors\*\***

Ryan J. Sullivan, Massachusetts General Hospital Cancer Center, Boston, MA

**AZD9291 activity in patients with leptomeningeal disease from non-small cell lung cancer: A phase I study\*\***

Dae Ho Lee, Asan Medical Center, Seoul, Korea

**4:30 p.m.-6:30 p.m.**

**Concurrent Session 5: Systems Biology**

Ballroom A

**Co-Chairpersons: Trey Ideker**, University of California-San Diego, La Jolla, CA, and **Walter Kolch**, Systems Biology Ireland, Dublin, Ireland

**The Cancer Cell Map Initiative\***

Trey Ideker

**From the cancer landscape to personalized treatment\***

Lodewyk F. Wessels, Netherlands Cancer Institute, Amsterdam, The Netherlands

**Personalized cancer diagnostics and therapeutics based on the computational modeling of signal transduction networks\***

Walter Kolch

\*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.

†Short talk from proffered paper

# CONFERENCE SCHEDULE

## **Serial killing of tumor cells by cytotoxic T cells: Mechanisms and implications for therapy\***

Peter Friedl, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, and The University of Texas MD Anderson Cancer Center, Houston, TX

**4:30 p.m.-6:30 p.m.**

## **Concurrent Session 6: Advances in Targeting the Hormone Axis**

Ballroom C

**Co-Chairpersons: Johann S. de Bono**, Institute of Cancer Research, Sutton, United Kingdom, and **Peter S. Nelson**, Fred Hutchinson Cancer Research Center, Seattle, WA

## **Resistance mechanisms subverting the AR program in CRPC: Opportunities for new therapeutics**

Peter S. Nelson

## **Regulation of AR variants by BET bromodomains in prostate cancer\***

Scott M. Dehm, Masonic Cancer Center, University of Minnesota, Minneapolis, MN

## **Androgen receptor splice variants dimerize to regulate gene expression and promote castration-resistant cell growth\***

Yan Dong, Tulane University, New Orleans, LA

## **ARV-330: An androgen receptor PROTAC degrader for prostate cancer\*\***

**(not eligible for CME credit)**

James D. Winkler, Arvinas, Inc., New Haven, CT

## **TAS3681, a new type androgen receptor antagonist, suppresses ligand-independent AR activation through its AR downregulation activity\*\***

**(not eligible for CME credit)**

Daisuke Kajiwara, Taiho Pharmaceutical Co., Ltd., Tsukuba, Japan

## **RAD1901, an orally available selective estrogen receptor downregulator, has potent antitumor activity in in vitro and in vivo models of ER+ breast cancer\*\***

**(not eligible for CME credit)**

Teeru Bihani, Radius Health, Waltham, MA

\*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.

†Short talk from proffered paper

### **Combination strategies\***

Johann S. De Bono

**4:30 p.m.-6:30 p.m.**

### **Concurrent Session 7: Analysis of Single Cells**

Ballroom B

**Co-Chairpersons: Caroline Dive**, CRUK Manchester Institute, Manchester, United Kingdom, and **Daniel A. Haber**, Massachusetts General Hospital, Charlestown, MA

#### **Using CTCs to improve outcomes in SCLC: Single cell profiling, ex vivo cultures, and mouse models\***

Caroline Dive

#### **Fluid biopsy in prostate cancer, from biochemical relapse to castrate resistance**

Peter Kuhn, University of Southern California, Los Angeles, CA

#### **Microfluidic isolation and molecular analysis of single CTCs**

Daniel A. Haber

#### **Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq\***

Itay Tirosh, The Broad Institute of MIT and Harvard, Cambridge, MA

**4:30 p.m.-6:30 p.m.**

### **Concurrent Session 8: Cancer Epigenetics and Metabolism**

Veterans Memorial Auditorium

**Co-Chairpersons: Ross L. Levine**, Memorial Sloan Kettering Cancer Center, New York, NY, and **Roger Stupp**, University Hospital Zürich, Zürich, Switzerland

#### **Role of mutations in epigenetic regulators in pathogenesis of myeloid malignancies\***

Ross L. Levine

#### **Metabolic adaptations and liabilities of TCA cycle-truncated tumors\***

Eyal Gottlieb, Cancer Research UK, Beatson Institute, Glasgow, United Kingdom

\*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.

# CONFERENCE SCHEDULE

## **Title to be announced**

Roger Stupp

## **Targeting super-enhancer driven transcriptional dependencies in cancer\***

Rani E. George, Dana-Farber Cancer Institute, Boston, MA

**6:00 p.m.-8:00 p.m.**

## **AACR Women in Cancer Research (WICR) Career Mentoring Session and Reception**

**(not eligible for CME credit)**

Room 210

**Co-Chairpersons: Patricia M. LoRusso**, Yale Cancer Center, New Haven, CT, and **Lillian L. Siu**, Princess Margaret Cancer Center, Toronto, ON, Canada

## **Keynote Address:**

### **Eyes wide open: Tips on preparing for a career in research**

Joan S. Brugge, Harvard Medical School, Boston, MA

## **Roundtables with Mentors**

See page 15 for details.

## SUNDAY, NOVEMBER 8, 2015

**7:00 a.m.-8:00 a.m.**

## **Continental Breakfast**

Boylston Street Hallway

**8:00 a.m.-10:00 a.m.**

## **Plenary Session 4: Advances in Targeted Therapy**

Veterans Memorial Auditorium

**Co-Chairpersons: José Baselga**, Memorial Sloan Kettering Cancer Center, New York, NY, and **Josep Tabernero**, Vall d'Hebron University Hospital, Barcelona, Spain

## **Targeting driving genomic mutations in breast cancer**

José Baselga

\*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.

**Title to be announced**

Jeffrey A. Engelman, Massachusetts General Hospital,  
Boston, MA

**Basket studies: Lessons learned and future directions\***

David Hyman, Memorial Sloan Kettering Cancer Center,  
New York, NY

**Dissecting colorectal cancer in multiple targetable subtypes**

Josep Tabernero

**The first reported results of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a phase I study of patients with advanced IDH1-mutant solid tumors, including gliomas\***

Howard A. Burris, III, Sarah Cannon Research Institute,  
Nashville, TN

**10:00 a.m.-10:20 a.m.**

**Break**

Boylston Street Hallway

**10:20 a.m.-12:20 p.m.**

**Plenary Session 5: Advances in Targeted DNA Repair**

Veterans Memorial Auditorium

**Co-Chairpersons: Alan D. D'Andrea**, Dana-Farber Cancer Institute, Boston, MA, and **Jean-Charles Soria**, Institut Gustave-Roussy, Villejuif, France

**ERCC1 alternative readouts\***

Jean-Charles Soria

**Synthetic lethal interaction between homologous recombination repair and POLQ-mediated alternative end-joining\***

Alan D. D'Andrea

**Exploiting cancer replication stress using pharmacological inhibitors of ATR and WEE1**

Mark J. O'Connor, AstraZeneca, Cheshire, United Kingdom

\*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.

# CONFERENCE SCHEDULE

## **PARP trapping versus PARP catalytic inhibition and coupling with TDP1\***

Yves G. Pommier, National Cancer Institute-CCR, Bethesda, MD

## **Phase 1 trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor VX-970 as monotherapy (mono) or in combination with carboplatin (CP) in advanced cancer patients (pts) with preliminary evidence of target modulation and antitumor activity\***

Timothy A. Yap, Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom

**12:30 p.m.-4:00 p.m.**

### **Exhibit Show**

Exhibit Hall C-D

**12:30 p.m.-3:30 p.m.**

### **Poster Session C**

**(not eligible for CME credit)**

Exhibit Hall C-D

Apoptosis, Necrosis, and Autophagy

Biomarkers

Cancer Stem Cells

Cellular Responses to Therapy

Chemistry

Clinical Trials

DNA Repair and Modulation

Drug Metabolism, Transport, and Biodistribution

Drug Resistance and Modifiers

Epigenetic Targets

Gene Therapies

Hormonal Agents and Therapy

Immune Mechanisms Invoked by Radiation Therapy

Immune Response to Therapies

Metabolism

\*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.



Monoclonal Antibodies  
New Molecular Targets  
Other Topics  
Radiotherapeutics  
RNA and RNA-based Technologies and Therapies  
Target Identification and Validation  
Therapeutic Agents: Biological  
Therapeutic Agents: Other  
Therapeutic Agents: Small Molecule Kinase Inhibitors  
Tumor Suppressors  
Immune Modulators  
Late-Breaking Posters

**3:45 p.m.-4:25 p.m.**

**Spotlight on Proffered Papers 3  
(not eligible for CME credit)**

Veterans Memorial Auditorium

**Chairperson: Manuel Hidalgo**, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain

**Phase 1 study of a novel PARP1/2 selective inhibitor, BGB-290\*†**

Jason Yang, Nucleus Network, Melbourne, Australia

**Discovery and preclinical evaluation of cEt-modified KRAS antisense oligonucleotide inhibitors\*†**

Alexey S. Revenko, Isis Pharmaceuticals, Carlsbad, CA

**Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions\*†**

David S. Hong, The University of Texas MD Anderson Cancer Center, Houston, TX

\*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.

†Short talk from proffered paper

# CONFERENCE SCHEDULE

**4:30 p.m.-6:30 p.m.**

## **Plenary Session 6: Resistance to Targeted Therapy**

Veterans Memorial Auditorium

**Co-Chairpersons: Levi A. Garraway**, Dana-Farber Cancer Institute, Boston, MA, and **Richard M. Marais**, Cancer Research UK Manchester Institute, Manchester, United Kingdom

### **Identifying determinants of response and resistance to targeted therapy and immunotherapy**

Levi A. Garraway

### **Mechanisms of resistance of targeted therapies in leukemia**

John C. Byrd, The Ohio State University Wexner Medical Center, Columbus, OH

### **Targeting BCL2 family proteins to increase the efficacy of cancer therapies**

Joan S. Brugge, Harvard Medical School, Boston, MA

### **Precision medicine protocols to circumvent resistance to targeted therapy in melanoma**

Richard M. Marais

## MONDAY, NOVEMBER 9, 2015

**7:00 a.m.-8:00 a.m.**

### **Continental Breakfast**

Boylston Street Hallway

**8:00 a.m.-10:00 a.m.**

## **Plenary Session 7: Tumor Microenvironment**

Veterans Memorial Auditorium

**Co-Chairpersons: Marina Y. Konopleva**, The University of Texas MD Anderson Cancer Center, Houston, TX, and **Christophe Massard**, Institut Gustave-Roussy, Villejuif, France

### **Altered metabolism in leukemic microenvironment\***

Marina Y. Konopleva

\*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.

**Tumor hypoxia and radiation resistance: Anything new on the horizon?\***

Eric Deutsch, Institut Gustave-Roussy, Villejuif, France

**The multifaceted role of Notch signaling in tumor/microenvironment interaction\***

Jon C. Aster, Brigham and Women's Hospital, Boston, MA

**Notch inhibitor in clinic**

Christophe Massard

**10:00 a.m.-10:20 a.m.**

**Break**

Boylston Street Hallway

**10:20 a.m.-12:20 p.m.**

**Plenary Session 8: The In Vitro Patient**

Veterans Memorial Auditorium

**Co-Chairpersons: James H. Doroshow**, National Cancer Institute-DCTD, Bethesda, MD, and **Emile E. Voest**, Netherlands Cancer Institute, Amsterdam, The Netherlands

**Use of tumor organoids in personalized medicine**

Emile E. Voest

**NCI patient-derived models repository\***

James H. Doroshow

**Ovarian PDX models: Of Mice and (Wo)men... and personalized treatment\***

Paul Haluska, Merck Research Laboratories, Rahway, NJ

**High-throughput drug screens in cancer cell models to enable precision cancer medicine\***

Mathew Garnett, Wellcome Trust Sanger Institute, Cambridge, United Kingdom

**12:20 p.m.-12:30 p.m.**

**Closing Remarks**

**(not eligible for CME credit)**

Veterans Memorial Auditorium

Levi A. Garraway, Dana-Farber Cancer Institute, Boston, MA

\*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.